Cardiovascular risk in rheumatic diseases

1. Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 2013 Jun 27; 38(6): 1092–1104.

2. Murray CJ, Vos T, Lozano R et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012 Dec 15; 380(9859): 2197–2223.

3. Catapano AL, Reiner Z, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011 Jul; 217(1): 3–46.

4. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005 Apr 21; 352(16): 1685–1695.

5. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991 Jan; 121(1 Pt 2): 293–298.

6. Kerekes G, Soltesz P, Nurmohamed MT et al. Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nature reviews Rheumatology 2012 Apr; 8(4): 224–234.

7. Emerging Risk Factors Collaboration; Kaptoge S, Di Angelantonio E, Lowe G et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010 Jan 9; 375(9709): 132–140.

8. Paul A, Yeh ET, Chan L. A proatherogenic role for C-reactive protein in vivo. Curr Opin Lipidol 2005 Oct; 16(5): 512–517.

9. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001 Mar 6; 103(9): 1194–1197.

10. Kim SH, Lee CK, Lee EY et al. Serum oxidized low-density lipoproteins in rheumatoid arthritis. Rheumatol Int 2004 Jul; 24(4): 230–233.

11. Lopez-Mejias R, Genre F, Gonzalez-Juanatey C, Gonzalez-Gay MA. Autoantibodies and biomarkers of endothelial cell activation in atherosclerosis. Vasa 2014 Mar; 43(2): 83–85.

12. Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherotrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009 Dec 1; 54(23): 2129–2138.

13. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012 Sep; 32(9): 2045–2051.

14. Hansson GK, Robertson AK, Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol 2006; 1: 297–329.

15. Sherer Y, Tenenbaum A, Praprotnik S, Shemesh J et al. Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, beta-2-glycoprotein-I, and oxidized LDL antibodies. Cardiology 2001; 95(1): 20–24.

16. Inoue T, Uchida T, Kamishirado H et al. Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease. J Am Coll Cardiol 2001 Jun 1; 37(7): 1871–1876.

17. Kobayashi K, Lopez LR, Matsuura E. Atherogenic antiphospholipid antibodies in antiphospholipid syndrome. Ann N Y Acad Sci 2007 Jun; 1108: 489–496.

18. Hasunuma Y, Matsuura E, Makita Z et al. Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997 Mar; 107(3): 569–573.

19. Jara LJ, Medina G, Vera-Lastra O, Amigo MC. Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases. Autoimmun Rev 2006 Mar; 5(3): 195–201.

20. Gurlek A, Ozdol C, Pamir G et al. Association between anticardiolipin antibodies and recurrent cardiac events in patients with acute coronary syndrome. Int Heart J 2005 Jul; 46(4): 631–638.

21. Matsuura E, Kobayashi K, Inoue K et al. Oxidized LDL/beta2-glycoprotein I complexes: new aspects in atherosclerosis. Lupus 2005; 14(9): 736–741.

22. Grainger DJ, Bethell HW. High titres of serum antinuclear antibodies, mostly directed against nucleolar antigens, are associated with the presence of coronary atherosclerosis. Ann Rheum Dis 2002 Feb; 61(2): 110–114.

23. Liang KP, Kremers HM, Crowson CS et al. Autoantibodies and the risk of cardiovascular events. J Rheumatol 2009 Nov; 36(11): 2462–2469.

24. Majka DS, Chang RW. Is preclinical autoimmunity benign? The case of cardiovascular disease. Rheum Dis Clin North Am 2014 Nov; 40(4): 659–668.

25. Payne RA. Cardiovascular risk. Br J Clin Pharmacol 2012 Sep; 74(3): 396–410.

26. D'Agostino RB sr., Vasan RS, Pencina MJ et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008 Feb 12; 117(6): 743–753.

27. Donnan PT, Donnelly L, New JP, Morris AD. Derivation and validation of a prediction score for major coronary heart disease events in a U.K. type 2 diabetic population. Diabetes Care 2006 Jun; 29(6): 1231–1236.

28. Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003 Jun; 24(11): 987–1003.

29. Greenland P, Alpert JS, Beller GA et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010 Dec 21; 122(25): 2748–2764.

30. Wasko MC. Comorbid conditions in patients with rheumatic diseases: an update. Curr Opin Rheumatol 2004 Mar; 16(2): 109–113.

31. Zinger H, Sherer Y, Shoenfeld Y. Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings. Clin Rev Allergy Immunol 2009 Aug; 37(1): 20–28.

32. Amaya-Amaya J, Montoya-Sanchez L, Rojas-Villarraga A. Cardiovascular involvement in autoimmune diseases. Biomed Res Int 2014; 2014: 367359.

33. Prasad M, Hermann J, Gabriel SE et al. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol 2015 Mar; 12(3): 168–176.

34. Sarmiento-Monroy JC, Amaya-Amaya J, Espinosa-Serna JS et al. Cardiovascular disease in rheumatoid arthritis: a systematic literature review in Latin America. Arthritis 2012; 2012: 371909.

35. Ramonda R, Lo Nigro A, Modesti V et al. Atherosclerosis in psoriatic arthritis. Autoimmun Rev 2011 Oct; 10(12): 773–778.

36. Husni ME. Comorbidities in Psoriatic Arthritis. Rheum Dis Clin North Am 2015 Nov; 41(4): 677–698.

37. Goodson NJ, Brookhart AM, Symmons DP et al. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 2009 Mar; 68(3): 367–372.

38. Peters MJ, Symmons DP, McCarey D et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010 Feb; 69(2): 325–331.

39. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008 Jan; 47(1): 72–75.

40. Hallgren R, Berne C. Glucose intolerance in patients with chronic inflammatory diseases is normalized by glucocorticoids. Acta Med Scand 1983; 213(5): 351–355.

41. Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol 2015 Dec; 11(12): 693–704.

42. Kawashiri SY, Kawakami A, Yamasaki S et al. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int 2011 Apr; 31(4): 451–456.

43. Micha R, Imamura F, Wyler von Ballmoos M et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011 Nov 1; 108(9): 1362–1370.

44. Westlake SL, Colebatch AN, Baird J et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 2011 Mar; 50(3): 518–531.

45. Roubille C, Richer V, Starnino T et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015 Mar; 74(3): 480–489.

46. Daien CI, Duny Y, Barnetche T et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 2012 Jun; 71(6): 862–868.

47. Antohe JL, Bili A, Sartorius JA et al. Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor alpha therapy. Arthritis Care Res (Hoboken) 2012 Feb; 64(2): 215–221.

48. Dixon WG, Watson KD, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium; Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007 Sep; 56(9): 2905–2912.

49. Martin-Martinez MA, Gonzalez-Juanatey C, Castaneda S et al. Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: scientific evidence and expert opinion. Semin Arthritis Rheum 2014 Aug; 44(1): 1–8.

50. Kaneko Y, Takeuchi T. A paradigm shift in rheumatoid arthritis over the past decade. Intern Med 2014; 53(17): 1895–1903.

51. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003 May 15; 423(6937): 356–361.

52. van Halm VP, Peters MJ, Voskuyl AE et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 2009 Sep; 68(9): 1395–1400.

53. Sokolove J, Brennan MJ, Sharpe O et al. Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum 2013 Jul; 65(7): 1719–1724.

54. Chung CP, Oeser A, Avalos I et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2006; 8(6): R186.

55. Shoenfeld Y, Gerli R, Doria A et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005 Nov 22; 112(21): 3337–3347.

56. Gerli R, Bartoloni Bocci E, Sherer Y et al. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2008 May; 67(5): 724–725.

57. van Halm VP, Nielen MM, Nurmohamed MT et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007 Feb; 66(2): 184–188.

58. Munro R, Morrison E, McDonald AG et al. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997 Jun; 56(6): 374–377.

59. Park YB, Choi HK, Kim MY et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002 Aug 15; 113(3): 188–193.

60. Boers M, Nurmohamed MT, Doelman CJ et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003 Sep; 62(9): 842–845.

61. Vis M, Nurmohamed MT, Wolbink G et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005 Feb; 32(2): 252–255.

62. Spanakis E, Sidiropoulos P, Papadakis J et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006 Dec; 33(12): 2440–2446.

63. Popa C, Netea MG, Radstake T et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005 Feb; 64(2): 303–305.

64. Georgiadis AN, Papavasiliou EC, Lourida ES et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment – a prospective, controlled study. Arthritis Res Ther 2006; 8(3): R82.

65. Popa C, van den Hoogen FH, Radstake TR et al. Modulation of lipoprotein plasma concentrations during long term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007 Nov; 66(11): 1503–1507.

66. Peters MJ, Vis M, van Halm VP et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 2007 Jul; 66(7): 958–961.

67. Boumpas DT, Austin HA 3rd, Fessler BJ et al. Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 1995 Jun 15; 122(12): 940–950.

68. Boumpas DT, Fessler BJ, Austin HA, 3rd et al. Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 1995 Jul 1; 123(1): 42–53.

69. Bertsias G, Ioannidis JP, Boletis J et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008 Feb; 67(2): 195–205.

70. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 2013 Aug; 43(1): 77–95.

71. de Carvalho JF, Bonfa E, Borba EF. Systemic lupus erythematosus and "lupus dyslipoproteinemia". Autoimmun Rev 2008 Jan; 7(3): 246–250.

72. Roman MJ, Shanker BA, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003 Dec 18; 349(25): 2399–2406.

73. Plazak W, Gryga K, Milewski M et al. Association of heart structure and function abnormalities with laboratory findings in patients with systemic lupus erythematosus. Lupus 2011 Aug; 20(9): 936–944.

74. Gustafsson JT, Simard JF, Gunnarsson I et al. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther 2012; 14(2): R46.

75. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am 2015 Nov; 41(4): 545–568.

76. Mok CC, Ko GT, Ho LY et al. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 2011 Feb; 63(2): 195–202.

77. Oliviero F, Sfriso P, Baldo G et al. Apolipoprotein A-I and cholesterol in synovial fluid of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Clin Exp Rheumatol 2009 Jan-Feb; 27(1): 79–83.

78. Kimhi O, Caspi D, Bornstein NM et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007 Feb; 36(4): 203–209.

79. Angel K, Provan SA, Gulseth HL et al. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 2010 Feb; 55(2): 333–338.

80. Allcock RJ, Forrest I, Corris PA et al. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology 2004 May; 43(5): 596–602.

81. Guiducci S, Giacomelli R, Cerinic MM. Vascular complications of scleroderma. Autoimmun Rev 2007 Sep; 6(8): 520–523.

82. Belch JJ, McSwiggan S, Lau C. Macrovascular disease in systemic sclerosis: the tip of an iceberg? Rheumatology 2008 Oct; 47(Suppl. 5): v16–17.

83. Hettema ME, Bootsma H, Kallenberg CG. Macrovascular disease and atherosclerosis in SSc. Rheumatology 2008 May; 47(5): 578–583.

84. Belloli L, Carlo-Stella N, Ciocia G et al. Myocardial involvement in systemic sclerosis. Rheumatology 2008 Jul; 47(7): 1070–1072.

85. Sulli A, Ghio M, Bezante GP et al. Blunted coronary flow reserve in systemic sclerosis. Rheumatology 2004 Apr; 43(4): 505–509.

86. Bartoli F, Blagojevic J, Bacci M et al. Flow-mediated vasodilation and carotid intima-media thickness in systemic sclerosis. Ann N Y Acad Sci 2007 Jun; 1108: 283–290.

87. Stafford L, Englert H, Gover J, Bertouch J. Distribution of macrovascular disease in scleroderma. Ann Rheum Dis 1998 Aug; 57(8): 476–479.

88. Szucs G, Timar O, Szekanecz Z et al. Endothelial dysfunction precedes atherosclerosis in systemic sclerosis – relevance for prevention of vascular complications. Rheumatology 2007 May; 46(5): 759–762.

89. Borba EF, Borges CT, Bonfa E. Lipoprotein profile in limited systemic sclerosis. Rheumatology international 2005 Jun; 25(5): 379–383.

90. Herrick AL, Illingworth KJ, Hollis S et al. Antibodies against oxidized low-density lipoproteins in systemic sclerosis. Rheumatology 2001 Apr; 40(4): 401–405.

91. Fatini C, Guiducci S, Abbate R, Matucci-Cerinic M. Vascular injury in systemic sclerosis: angiotensin-converting enzyme insertion/deletion polymorphism. Curr Rheumatol Rep 2004 Apr; 6(2): 149–155.

92. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975 Feb 13; 292(7): 344–347.

93. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975 Feb 20; 292(8): 403–407.

94. Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve 2015 May; 51(5): 638–656.

95. Ungprasert P, Suksaranjit P, Spanuchart I et al. Risk of coronary artery disease in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis of observational studies. Semin Arthritis Rheum 2014 Aug; 44(1): 63–67.

96. Linos E, Fiorentino D, Lingala B et al. Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey. Arthritis Res Ther 2013; 15(1): R7.

97. de Moraes MT, de Souza FH, de Barros TB, Shinjo SK. Analysis of metabolic syndrome in adult dermatomyositis with a focus on cardiovascular disease. Arthritis Care Res (Hoboken) 2013 May; 65(5): 793–799.

98. Limaye VS, Lester S, Blumbergs P, Roberts-Thomson PJ. Idiopathic inflammatory myositis is associated with a high incidence of hypertension and diabetes mellitus. Int J Rheum Dis 2010 May; 13(2): 132–137.

99. Agca R, Heslinga SC, Rollefstad S et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2016 Oct 3, pii: annrheumdis-2016-209775 [Epub ahead of print].

100. Kawai VK, Chung CP, Solus JF et al. The ability of the 2013 American College of Cardiology/American Heart Association cardiovascular risk score to identify rheumatoid arthritis patients with high coronary artery calcification scores. Arthritis Rheumatol 2015 Feb; 67(2): 381–385.

101. Tournadre A, Tatar Z, Pereira B et al. Application of the European Society of Cardiology, Adult Treatment Panel III and American College of Cardiology/American Heart Association guidelines for cardiovascular risk management in a French cohort of rheumatoid arthritis. Int J Cardiol 2015 Mar 15; 183: 149–154.

102. Ward MM. Recent improvements in survival in patients with rheumatoid arthritis: better outcomes or different study designs? Arthritis Rheum 2001 Jun; 44(6): 1467–1469.

103. Innala L, Moller B, Ljung L et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 2011; 13(4): R131.

104. Myasoedova E, Crowson CS, Nicola PJ et al. The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol 2011 Aug; 38(8): 1601–1606.

105. Lopez-Longo FJ, Oliver-Minarro D, de la Torre I et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009 Apr 15; 61(4): 419–424.

106. Gomez-Vaquero C, Robustillo M, Narvaez J et al. Assessment of cardiovascular risk in rheumatoid arthritis: impact of the new EULAR recommendations on the score cardiovascular risk index. Clin Rheumatol 2012 Jan; 31(1): 35–39.

107. Greenland P, Alpert JS, Beller GA et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010 Dec 14; 56(25): e50–103.

108. Vlachopoulos C, Aznaouridis K, Terentes-Printzios D et al. Prediction of cardiovascular events and all-cause mortality with brachial-ankle elasticity index: a systematic review and meta-analysis. Hypertension 2012 Aug; 60(2): 556–562.

109. Stein JH, Korcarz CE, Hurst RT et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008 Feb; 21(2): 93–111; quiz 189–190.

110. McCarey DW, McInnes IB, Madhok R et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004 Jun 19; 363(9426): 2015–2021.

111. Choi HK, Hernan MA, Seeger JD et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002 Apr 6; 359(9313): 1173–1177.

112. Jacobsson LT, Turesson C, Gulfe A et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005 Jul; 32(7): 1213–1218.

113. van Halm VP, Nurmohamed MT, Twisk JW et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006; 8(5): R151.

114. Naranjo A, Sokka T, Descalzo MA et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008; 10(2): R30.

115. Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998 Jun; 25(6): 1072–1077.

116. Bavry AA, Khaliq A, Gong Y et al. Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. Am J Med 2011 Jul; 124(7): 614–620.

117. Ruyssen-Witrand A, Fautrel B, Saraux A et al. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2011 Jan; 78(1): 23–30.